title: ÐÐ±Ð¾ÑÐ½Ð¾Ð²Ð°Ð½Ð¸Ðµ ÐºÑÐ¸ÑÐµÑÐ¸ÐµÐ² Ð²ÑÐ¿Ð¸ÑÐºÐ¸ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ° Ð¿Ð¾ÑÐ»Ðµ ÑÐ°Ð´Ð¸Ð¾Ð½ÑÐºÐ»Ð¸Ð´Ð½Ð¾Ð¹ ÑÐµÑÐ°Ð¿Ð¸Ð¸ Ð´Ð¸Ñ Ð»Ð¾ÑÐ¸Ð´Ð¾Ð¼ Ra-223
title: Ð²ÑÐ¿ÑÑÐºÐ½Ð°Ñ ÐºÐ²Ð°Ð»Ð¸ÑÐ¸ÐºÐ°ÑÐ¸Ð¾Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð¼Ð°Ð³Ð¸ÑÑÑÐ°
titleType: Subtitle
title: Evaluation of the criteria for release of a patient after radionuclide therapy with Ra-223 dichloride
Creators: name: ÐÐµÐ»Ð¸ÑÐºÐ¸Ð½Ð°, ÐÑÐ¸ÑÑÐ¸Ð½Ð°
Publisher: name: Ð¡Ð°Ð½ÐºÑ-ÐÐµÑÐµÑÐ±ÑÑÐ³ÑÐºÐ¸Ð¹ Ð¿Ð¾Ð»Ð¸ÑÐµÑÐ½Ð¸ÑÐµÑÐºÐ¸Ð¹ ÑÐ½Ð¸Ð²ÐµÑÑÐ¸ÑÐµÑ ÐÐµÑÑÐ° ÐÐµÐ»Ð¸ÐºÐ¾Ð³Ð¾
Year: 2024
Subjects: ÑÐ°Ð´Ð¸Ð¾Ð½ÑÐºÐ»Ð¸Ð´Ð½Ð°Ñ ÑÐµÑÐ°Ð¿Ð¸Ñ
ÑÐ°Ð´Ð¸Ð¾ÑÐ°ÑÐ¼Ð¿ÑÐµÐ¿Ð°ÑÐ°ÑÑ
ÑÐ°Ð´Ð¸Ð°ÑÐ¸Ð¾Ð½Ð½Ð°Ñ Ð±ÐµÐ·Ð¾Ð¿Ð°ÑÐ½Ð¾ÑÑÑ
ÐºÑÐ¸ÑÐµÑÐ¸Ð¸ Ð²ÑÐ¿Ð¸ÑÐºÐ¸ Ð¿Ð¾ÑÐ»Ðµ ÑÐ°Ð´Ð¸Ð¾Ð½ÑÐºÐ»Ð¸Ð´Ð½Ð¾Ð¹ ÑÐµÑÐ°Ð¿Ð¸Ð¸
radionuclide therapy
radiopharmaceuticals
radiation safety
discharge criteria after radionuclide therapy

description: Ð¢ÐµÐ¼Ð° Ð²ÑÐ¿ÑÑÐºÐ½Ð¾Ð¹ ÐºÐ²Ð°Ð»Ð¸ÑÐ¸ÐºÐ°ÑÐ¸Ð¾Ð½Ð½Ð¾Ð¹ ÑÐ°Ð±Ð¾ÑÑ: Â«ÐÐ±Ð¾ÑÐ½Ð¾Ð²Ð°Ð½Ð¸Ðµ ÐºÑÐ¸ÑÐµÑÐ¸ÐµÐ² Ð²ÑÐ¿Ð¸ÑÐºÐ¸ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ° Ð¿Ð¾ÑÐ»Ðµ ÑÐ°Ð´Ð¸Ð¾Ð½ÑÐºÐ»Ð¸Ð´Ð½Ð¾Ð¹ ÑÐµÑÐ°Ð¿Ð¸Ð¸ Ð´Ð¸ÑÐ»Ð¾ÑÐ¸Ð´Ð¾Ð¼ Ra-223Â». Ð¦ÐµÐ»Ñ ÑÐ°Ð±Ð¾ÑÑ Ð·Ð°ÐºÐ»ÑÑÐ°Ð»Ð°ÑÑ Ð² Ð¾ÑÐµÐ½ÐºÐµ Ð´Ð¾Ð· Ñ ÐºÑÐ¸ÑÐ¸ÑÐµÑÐºÐ¸Ñ Ð³ÑÑÐ¿Ð¿ Ð½Ð°ÑÐµÐ»ÐµÐ½Ð¸Ñ Ð² ÑÑÐ°Ð½ÑÐ¿Ð¾ÑÑÐµ Ð¿ÑÐ¸ Ð¿ÐµÑÐµÐ¼ÐµÑÐµÐ½Ð¸Ð¸ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ° Ð´Ð¾ Ð¼ÐµÑÑÐ° Ð¿ÑÐ¾Ð¶Ð¸Ð²Ð°Ð½Ð¸Ñ Ð¿Ð¾ÑÐ»Ðµ ÑÐ°Ð´Ð¸Ð¾Ð½ÑÐºÐ»Ð¸Ð´Ð½Ð¾Ð¹ ÑÐµÑÐ°Ð¿Ð¸Ð¸ Ñ Ð¿ÑÐµÐ¿Ð°ÑÐ°ÑÐ¾Ð¼ Ð´Ð¸ÑÐ»Ð¾ÑÐ¸Ð´Ð¾Ð¼ Ra-223 c ÑÑÑÑÐ¾Ð¼ Ð¾Ð±ÑÐ°Ð·Ð¾Ð²Ð°Ð½Ð¸Ñ Ð±Ð¸Ð¾Ð»Ð¾Ð³Ð¸ÑÐµÑÐºÐ¸Ñ Ð¾ÑÑÐ¾Ð´Ð¾Ð², ÑÐ¾Ð´ÐµÑÐ¶Ð°ÑÐ¸Ñ Ra-223. ÐÐ»Ñ Ð´Ð¾ÑÑÐ¸Ð¶ÐµÐ½Ð¸Ñ Ð´Ð°Ð½Ð½Ð¾Ð¹ ÑÐµÐ»Ð¸ Ð±ÑÐ»Ð¸ Ð¿Ð¾ÑÑÐ°Ð²Ð»ÐµÐ½Ñ ÑÐ»ÐµÐ´ÑÑÑÐ¸Ðµ Ð·Ð°Ð´Ð°ÑÐ¸: 1.Ð Ð°Ð·ÑÐ°Ð±Ð¾ÑÐ°ÑÑ ÑÑÐµÐ½Ð°ÑÐ¸Ð¸ Ð¾Ð±Ð»ÑÑÐµÐ½Ð¸Ñ Ð»Ð¸Ñ Ð¸Ð· Ð½Ð°ÑÐµÐ»ÐµÐ½Ð¸Ñ Ð² ÑÑÐ°Ð½ÑÐ¿Ð¾ÑÑÐµ Ð¿ÑÐ¸ Ð¿ÐµÑÐµÐ¼ÐµÑÐµÐ½Ð¸Ð¸ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ° Ð´Ð¾ Ð¼ÐµÑÑÐ° Ð¶Ð¸ÑÐµÐ»ÑÑÑÐ²Ð°; 2.ÐÑÐµÐ½ÐºÐ° Ð´Ð¸Ð½Ð°Ð¼Ð¸ÐºÐ¸ Ð¸Ð·Ð¼ÐµÐ½ÐµÐ½Ð¸Ñ Ð°ÐºÑÐ¸Ð²Ð½Ð¾ÑÑÐ¸ Ð² ÑÐµÐ»Ðµ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ° Ð¸ Ð±Ð°ÐºÐ¾Ð² Ð±Ð¸Ð¾ÑÑÐ°Ð»ÐµÑÐ¾Ð² Ð² ÑÑÐ°Ð½ÑÐ¿Ð¾ÑÑÐµ Ð²Ð¾ Ð²ÑÐµÐ¼Ñ Ð½Ð°ÑÐ¾Ð¶Ð´ÐµÐ½Ð¸Ñ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ° Ð² ÑÑÐ°Ð½ÑÐ¿Ð¾ÑÑÐ½Ð¾Ð¼ ÑÑÐµÐ´ÑÑÐ²Ðµ; 3.ÐÐ¾Ð´ÐµÐ»Ð¸ÑÐ¾Ð²Ð°Ð½Ð¸Ðµ Ð¾Ð±Ð»ÑÑÐµÐ½Ð¸Ñ Ð»Ð¸Ñ Ð¸Ð· ÐºÑÐ¸ÑÐ¸ÑÐµÑÐºÐ¸Ñ Ð³ÑÑÐ¿Ð¿ Ð¸Ð· Ð½Ð°ÑÐµÐ»ÐµÐ½Ð¸Ñ Ð²Ð¾ Ð²ÑÐµÐ¼Ñ ÐºÐ¾Ð½ÑÐ°ÐºÑÐ° Ñ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð¼ Ð¸ ÐµÐ³Ð¾ Ð¾ÑÑÐ¾Ð´Ð°Ð¼Ð¸ Ð² ÑÑÐ°Ð½ÑÐ¿Ð¾ÑÑÐµ. 4. ÐÑÐµÐ½ÐºÐ° Ð´Ð¾Ð· Ð¾ÑÐ´ÐµÐ»ÑÐ½ÑÑ Ð»Ð¸Ñ Ð¸Ð· Ð½Ð°ÑÐµÐ»ÐµÐ½Ð¸Ñ Ð¿ÑÐ¸ Ð½Ð°ÑÐ¾Ð¶Ð´ÐµÐ½Ð¸Ð¸ Ð²Ð¼ÐµÑÑÐµ Ñ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð¼ Ð² Ð¿Ð¾ÐµÐ·Ð´Ðµ. 5. ÐÑÐµÐ½ÐºÐ° Ð´Ð¾Ð· Ð¾ÑÐ´ÐµÐ»ÑÐ½ÑÑ Ð»Ð¸Ñ Ð¸Ð· Ð½Ð°ÑÐµÐ»ÐµÐ½Ð¸Ñ Ð¿ÑÐ¸ Ð½Ð°ÑÐ¾Ð¶Ð´ÐµÐ½Ð¸Ð¸ Ð²Ð¼ÐµÑÑÐµ Ñ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð¼ Ð² ÑÐ°Ð¼Ð¾Ð»ÑÑÐµ.
description: Topic of the final qualification work: âEvaluation of the criteria for release of a pa-tient after radionuclide therapy with Ra-223 dichlorideâ. The purpose of the work was to assess doses in critical groups of the population when moving a patient on public transport to their place of residence after radionuclide therapy with the drug Ra-223 dichloride, taking into account the formation of biological waste containing Ra-223. To achieve this goal, the following tasks were set: 1. Develop scenarios for exposure of members of the public in transport when a patient moving to his place of residence; 2.Assessment of the dynamics of changes in activity in the patientâs body and the tanks of dry closets in transport while the patient is in the vehicle; 3. Modeling of exposure of individuals from critical groups of the population during contact with the patient and his waste in transport. 4. Estimation of doses to individual members of the public when traveling with a patient on a train. 5. Estimation of doses to individual members of the public when traveling with a patient on an airplane.